STOCK TITAN

Innate Pharma Announces Its Participation in Upcoming Investor Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has announced its participation in the upcoming BTIG Virtual Biotechnology Conference, scheduled for August 5-6, 2024. The company will be represented by key executives, including Yannis Morel, EVP and Chief Operating Officer, and Arvind Sood, EVP and President of US Operations.

This virtual conference provides an opportunity for Innate Pharma to engage with investors and showcase its latest developments in the biotechnology sector. The company's presence at such events is important for maintaining investor relations and potentially attracting new investment opportunities.

Innate Pharma (Euronext Parigi: IPH; Nasdaq: IPHA) ha annunciato la sua partecipazione alla prossima BTIG Virtual Biotechnology Conference, programmata per 5-6 agosto 2024. L'azienda sarà rappresentata da dirigenti chiave, tra cui Yannis Morel, EVP e Chief Operating Officer, e Arvind Sood, EVP e Presidente delle Operazioni negli Stati Uniti.

Questa conferenza virtuale offre a Innate Pharma l'opportunità di interagire con gli investitori e mostrare i suoi ultimi sviluppi nel settore biotecnologico. La presenza dell'azienda a eventi di questo tipo è importante per mantenere le relazioni con gli investitori e potenzialmente attrarre nuove opportunità di investimento.

Innate Pharma (Euronext París: IPH; Nasdaq: IPHA) ha anunciado su participación en la próxima BTIG Virtual Biotechnology Conference, programada para 5-6 de agosto de 2024. La empresa estará representada por ejecutivos clave, incluyendo Yannis Morel, EVP y Director de Operaciones, y Arvind Sood, EVP y Presidente de las Operaciones en EE. UU.

Esta conferencia virtual brinda a Innate Pharma la oportunidad de interactuar con inversores y presentar sus últimos avances en el sector biotecnológico. La presencia de la empresa en eventos como este es crucial para mantener relaciones con los inversores y potencialmente atraer nuevas oportunidades de inversión.

Innate Pharma (유로넥스트 파리: IPH; 나스닥: IPHA)가 다가오는 BTIG 가상 생명공학 컨퍼런스에 참석한다고 발표했습니다. 이 행사는 2024년 8월 5-6일로 예정되어 있습니다. 회사는 Yannis Morel, EVP 및 최고 운영 책임자, Arvind Sood, EVP 및 미국 운영 사장이 대표로 참석합니다.

이번 가상 회의는 Innate Pharma가 투자자와 소통하고 생명공학 분야의 최신 개발 상황을 알릴 수 있는 기회를 제공합니다. 이러한 행사에 대한 회사의 참여는 투자자 관계를 유지하고 잠재적으로 새로운 투자 기회를 유치하는 데 중요합니다.

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) a annoncé sa participation à la prochaine BTIG Virtual Biotechnology Conference, prévue pour les 5 et 6 août 2024. L'entreprise sera représentée par des dirigeants clés, dont Yannis Morel, EVP et directeur des opérations, et Arvind Sood, EVP et président des opérations aux États-Unis.

Cette conférence virtuelle offre à Innate Pharma l'occasion d'interagir avec les investisseurs et de présenter ses dernières avancées dans le secteur biotechnologique. La présence de l'entreprise à de tels événements est essentielle pour entretenir les relations avec les investisseurs et potentiellement attirer de nouvelles opportunités d'investissement.

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) hat seine Teilnahme an der bevorstehenden BTIG Virtual Biotechnology Conference angekündigt, die für 5.-6. August 2024 geplant ist. Das Unternehmen wird von wichtigen Führungskräften vertreten, darunter Yannis Morel, EVP und Chief Operating Officer, sowie Arvind Sood, EVP und Präsident der US-Operationen.

Diese virtuelle Konferenz bietet Innate Pharma die Möglichkeit, mit Investoren in Kontakt zu treten und die neuesten Entwicklungen im Bereich Biotechnologie vorzustellen. Die Präsenz des Unternehmens bei solchen Veranstaltungen ist wichtig, um die Beziehungen zu Investoren zu pflegen und möglicherweise neue Investitionsmöglichkeiten zu gewinnen.

Positive
  • None.
Negative
  • None.

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced members of its executive team are scheduled to participate in the upcoming conference, detailed below. Participants will include Yannis Morel, EVP, Chief Operating Officer and Arvind Sood, EVP, President of US Operations.

  • BTIG Virtual Biotechnology Conference

Dates: August 5 - 6 2024 | Virtual

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.

Innate’s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET® multi-specific NK cell engagers to address multiple tumor types.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code
Ticker code
LEI

FR0010331421

Euronext: IPH Nasdaq: IPHA

9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe,” “potential,” “expect” and “will” and similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public, by the Company.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

For additional information, please contact:

Investors


Innate Pharma

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

Henry.wheeler@innate-pharma.fr

Media Relations

NewCap

Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

innate@newcap.eu

Source: Innate Pharma

FAQ

When is Innate Pharma (IPHA) participating in the BTIG Virtual Biotechnology Conference?

Innate Pharma (IPHA) is participating in the BTIG Virtual Biotechnology Conference on August 5-6, 2024.

Who will represent Innate Pharma (IPHA) at the BTIG Virtual Biotechnology Conference in August 2024?

Innate Pharma (IPHA) will be represented by Yannis Morel, EVP and Chief Operating Officer, and Arvind Sood, EVP and President of US Operations.

What type of event is the BTIG Biotechnology Conference that Innate Pharma (IPHA) is attending?

The BTIG Biotechnology Conference is a virtual event for biotechnology companies to engage with investors and showcase their developments.

Where is Innate Pharma (IPHA) listed on stock exchanges?

Innate Pharma (IPHA) is listed on Euronext Paris under the ticker IPH and on Nasdaq under the ticker IPHA.

Innate Pharma S.A. ADS

NASDAQ:IPHA

IPHA Rankings

IPHA Latest News

IPHA Stock Data

170.53M
80.95M
0.5%
0.08%
Biotechnology
Healthcare
Link
United States of America
Marseille